188 completed, 70 terminated, 41 active not recruiting, 24 recruiting. 370 Phase 1, 174 Phase 2.
Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-11-02 |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 40 | 2026-07-10 | 2026-07-13 |
| Combining Latency Reversing Agents to Address the HIV Reservoir Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Erasmus Medical Center | 30 | 2026-04-01 | 2026-02-03 |
| A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies JNJ-95566692, JNJ-87801493, loncastuximab tesirine - Lymphoma, Non-Hodgkin | Phase 1 | Recruiting | Janssen Research & Development, LLC | 340 | 2026-01-20 | 2026-11-03 |
| Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases. - Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2025-09-01 | 2025-08-21 |
| Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders. - EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-21 |
| Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients HuL001, Lenalidomide/Dexamethasone - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | HuniLife Biotechnology, Inc. | 21 | 2025-08-18 | 2026-09-18 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma Ramantamig, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 280 | 2024-12-04 | 2026-11-17 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | Recruiting | Vitebsk Regional Clinical Cancer Centre | 24 | 2024-05-14 | 2026-08-13 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Optimizing Reversal of HIV Latency With Combination Therapy Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 49 | 2024-04-01 | 2024-02-05 |
| A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Glofitamab, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma, MCL | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2024-01-08 | 2026-03-27 |
| Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Zanubrutinib, Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-01-01 | 2024-08-09 |
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma Cevostamab, Lenalidomide, Tocilizumab - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 200 | 2023-11-14 | 2026-11-05 |
| Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) Lenalidomide, Lenalidomide 25 MG Oral Capsule - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Starton Therapeutics, Inc | 24 | 2023-10-02 | 2026-08-24 |
Showing 20 of 370. Sign in to see all of them.
Multiple Myeloma (128) · Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lymphoma, Large B-Cell, Diffuse (40) · Lymphoma, Follicular (38) · Lymphoma, Mantle-Cell (30) · Recurrence (30) · Lymphoma (28) · Lymphoma, Non-Hodgkin (27) · Lymphoma, B-Cell, Marginal Zone (25) · Leukemia, Myeloid, Acute (19) · Neoplasms, Plasma Cell (19) · Myelodysplastic Syndromes (17) · Lymphoma, B-Cell (16) · Hodgkin Disease (14) · Burkitt Lymphoma (12)
National Cancer Institute (NCI) (28) · M.D. Anderson Cancer Center (23) · Celgene (14) · Mayo Clinic (13) · City of Hope Medical Center (9) · Massachusetts General Hospital (8) · Memorial Sloan Kettering Cancer Center (7) · Celgene Corporation (6) · Janssen Research & Development, LLC (6) · Case Comprehensive Cancer Center (5) · Hoffmann-La Roche (5) · Millennium Pharmaceuticals, Inc. (5) · Arbeitsgemeinschaft medikamentoese Tumortherapie (4) · Bristol-Myers Squibb (4) · Dana-Farber Cancer Institute (4)
United States (266) · France (33) · Germany (30) · Spain (29) · Italy (22) · Australia (18) · United Kingdom (18) · China (17) · Canada (15) · Netherlands (11) · Austria (10) · Belgium (10) · Japan (10) · South Korea (10) · Israel (7)
James R Berenson, MD (3) · Joseph M Tuscano (3) · Noopur Raje, MD (3) · Paul Richardson, MD (3) · Robert Knight, MD (3) · Shaji K. Kumar, M.D. (3) · Christopher J Melani, M.D. (2)
PMID 28314699, PMID 40802906, PMID 18056189, PMID 18824593, PMID 19011760, PMID 19182205, PMID 19451403, PMID 19965642, PMID 20385792, PMID 20508619, PMID 20724537, PMID 21149673, PMID 21596852, PMID 21816833, PMID 22033493, PMID 22422823, PMID 22451423, PMID 22517904, PMID 22546242, PMID 22640031, PMID 22665938, PMID 22677155, PMID 22915641, PMID 22936658, PMID 23085463, PMID 23100308, PMID 23242596, PMID 23417027, PMID 23447001, PMID 23592273, PMID 23676418, PMID 23756764, PMID 23834234, PMID 24004667, PMID 24014245, PMID 24351336, PMID 24562384, PMID 24761838, PMID 24914044, PMID 25052451, PMID 25082342, PMID 25135992, PMID 25210017, PMID 25456369, PMID 25824111, PMID 25837499, PMID 26058589, PMID 26284823, PMID 26331432, PMID 26337806
2023 (12), U01CA076576 (7), P30CA015083 (6), 2009 (5), 2015 (5), 2019 (5), P30CA016058 (5), P30CA043703 (4), UM1CA186712 (4), P30CA014599 (3), P30CA036727 (3), U10CA031946 (3), U10CA180821 (3), 2025 (2), N01CM00071 (2)